RU2002113759A - Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII - Google Patents
Соединения имидазола в качестве ингибиторов фосфодиэстеразы VIIInfo
- Publication number
- RU2002113759A RU2002113759A RU2002113759/04A RU2002113759A RU2002113759A RU 2002113759 A RU2002113759 A RU 2002113759A RU 2002113759/04 A RU2002113759/04 A RU 2002113759/04A RU 2002113759 A RU2002113759 A RU 2002113759A RU 2002113759 A RU2002113759 A RU 2002113759A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- compounds
- diseases
- imidazole
- solvates
- Prior art date
Links
- 150000002460 imidazoles Chemical class 0.000 title 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
Claims (7)
1. Соединения имидазола формулы
в которых R1 и R2, независимо друг от друга, обозначают А1, ОА1, SA1
или Hal;
А1 обозначает Н, А, алкенил, циклоалкил или алкиленциклоалкил;
А обозначает алкил, содержащий 1-10 атомов углерода;
Hal обозначает F, CI, Вг или I;
Х обозначает О, S, SO или SO2,
и их физиологически приемлемые соли и/или сольваты.
2. Соединения имидазола формулы I по п.1 и их физиологически приемлемые соли и сольваты в качестве медицинских препаратов.
3. Медицинские препараты по п.2 для ингибирования фосфодиэстеразы VII.
4. Медицинские препараты по п.3 для лечения аллергических заболеваний, астмы, хронического бронхита, атопического дерматита, псориаза и других кожных заболеваний, воспалительных заболеваний, аутоиммунных болезней, таких, как, например, ревматоидный артрит, рассеянный склероз, болезнь Крона, сахарный диабет или язвенный колит, остеопороз, реакции отторжения трансплантированной ткани, кахексия, рост опухолей или опухолевых метастазов, сепсис, расстройства памяти, атеросклероз и СПИД.
5. Фармацевтические препараты, содержащие, по крайней мере, один медицинский препарат по одному из пп.3 и 4, которые могут содержать также эксципиенты и/или вспомогательные вещества и другие активные ингредиенты.
6. Применение соединений формулы I по п.1 и/или их физиологически приемлемых солей или сольватов в приготовлении медицинских препаратов для лечения аллергических заболеваний, астмы, хронического бронхита, атопического дерматита, псориаза и других кожных заболеваний, воспалительных заболеваний, аутоиммунных болезней, таких, как, например, ревматоидный артрит, рассеянный склероз, болезнь Крона, сахарный диабет или язвенный колит, остеопороз, реакции отторжения трансплантированной ткани, кахексия, рост опухолей или опухолевых метастазов, сепсис, расстройства памяти, атеросклероз и СПИД.
7. Способ получения соединений формулы I по п.1 и их солей, отличающийся тем, что проводят реакцию соединений формулы II
в которой R1, R2 и Х соответствуют приведенным выше определениям;
L обозначает Cl, Br, ОН, SCH3 или активную этерифицированную группу ОН, с имидазолом,
и/или соединение формулы I преобразуют в одну из его солей.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19954707.6 | 1999-11-13 | ||
| DE19954707A DE19954707A1 (de) | 1999-11-13 | 1999-11-13 | Imidazolverbindungen als Phosphodiesterase VII-Hemmer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002113759A true RU2002113759A (ru) | 2004-01-10 |
Family
ID=7928973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002113759/04A RU2002113759A (ru) | 1999-11-13 | 2000-10-31 | Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6884800B1 (ru) |
| EP (1) | EP1228073B1 (ru) |
| JP (1) | JP4819272B2 (ru) |
| KR (1) | KR20020049051A (ru) |
| CN (1) | CN1390222A (ru) |
| AR (1) | AR026421A1 (ru) |
| AT (1) | ATE245653T1 (ru) |
| AU (1) | AU775886B2 (ru) |
| BR (1) | BR0015487A (ru) |
| CA (1) | CA2391087A1 (ru) |
| CZ (1) | CZ20021474A3 (ru) |
| DE (2) | DE19954707A1 (ru) |
| DK (1) | DK1228073T3 (ru) |
| ES (1) | ES2200968T3 (ru) |
| HU (1) | HUP0203422A3 (ru) |
| MX (1) | MXPA02004728A (ru) |
| NO (1) | NO20022232D0 (ru) |
| PL (1) | PL355098A1 (ru) |
| PT (1) | PT1228073E (ru) |
| RU (1) | RU2002113759A (ru) |
| SK (1) | SK6012002A3 (ru) |
| WO (1) | WO2001036425A2 (ru) |
| ZA (1) | ZA200204729B (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2217956B1 (es) * | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
| KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US8637528B2 (en) * | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| EP2139475B1 (en) * | 2007-03-27 | 2014-12-17 | Omeros Corporation | PDE7 inhibitors for use in the treatment of movement disorders |
| DE102007047738A1 (de) * | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Imidazolderivate |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20120115849A1 (en) | 2010-11-08 | 2012-05-10 | Demopulos Gregory A | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| JP7213863B2 (ja) | 2017-07-12 | 2023-01-27 | ダート・ニューロサイエンス・エルエルシー | Pde7阻害剤としての置換ベンゾオキサゾール及びベンゾフラン化合物 |
| EP4572765A1 (en) | 2022-08-18 | 2025-06-25 | Mitodicure GmbH | Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2919271A (en) * | 1957-12-05 | 1959-12-29 | Smith Kline French Lab | 3-amino-1, 2-dihydro-3h-pyrido [3, 2, 1-kl]-phenothiazines |
| DE69016430T2 (de) * | 1989-06-09 | 1995-06-01 | Upjohn Co | Heterozyklische amine mit zns-wirksamkeit. |
| US5318965A (en) * | 1990-08-24 | 1994-06-07 | Abbott Laboratories | Quinobenzoxazine, antineoplastic agents |
| ZA9810766B (en) * | 1997-11-28 | 1999-05-25 | Mochida Pharm Co Ltd | Novel compounds having cgmp-pde inhibitory activity |
-
1999
- 1999-11-13 DE DE19954707A patent/DE19954707A1/de not_active Withdrawn
-
2000
- 2000-10-31 CN CN00815534A patent/CN1390222A/zh active Pending
- 2000-10-31 MX MXPA02004728A patent/MXPA02004728A/es not_active Application Discontinuation
- 2000-10-31 WO PCT/EP2000/010765 patent/WO2001036425A2/de not_active Ceased
- 2000-10-31 KR KR1020027006131A patent/KR20020049051A/ko not_active Withdrawn
- 2000-10-31 CZ CZ20021474A patent/CZ20021474A3/cs unknown
- 2000-10-31 RU RU2002113759/04A patent/RU2002113759A/ru unknown
- 2000-10-31 ES ES00975978T patent/ES2200968T3/es not_active Expired - Lifetime
- 2000-10-31 AU AU13907/01A patent/AU775886B2/en not_active Ceased
- 2000-10-31 JP JP2001538914A patent/JP4819272B2/ja not_active Expired - Fee Related
- 2000-10-31 SK SK601-2002A patent/SK6012002A3/sk unknown
- 2000-10-31 EP EP00975978A patent/EP1228073B1/de not_active Expired - Lifetime
- 2000-10-31 US US10/129,629 patent/US6884800B1/en not_active Expired - Fee Related
- 2000-10-31 HU HU0203422A patent/HUP0203422A3/hu unknown
- 2000-10-31 DK DK00975978T patent/DK1228073T3/da active
- 2000-10-31 AT AT00975978T patent/ATE245653T1/de not_active IP Right Cessation
- 2000-10-31 CA CA002391087A patent/CA2391087A1/en not_active Abandoned
- 2000-10-31 DE DE50003036T patent/DE50003036D1/de not_active Expired - Lifetime
- 2000-10-31 PT PT00975978T patent/PT1228073E/pt unknown
- 2000-10-31 PL PL00355098A patent/PL355098A1/xx unknown
- 2000-10-31 BR BR0015487-3A patent/BR0015487A/pt not_active Application Discontinuation
- 2000-11-10 AR ARP000105929A patent/AR026421A1/es unknown
-
2002
- 2002-05-10 NO NO20022232A patent/NO20022232D0/no not_active Application Discontinuation
- 2002-06-12 ZA ZA200204729A patent/ZA200204729B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP4819272B2 (ja) | 2011-11-24 |
| EP1228073A2 (de) | 2002-08-07 |
| MXPA02004728A (es) | 2002-08-30 |
| ES2200968T3 (es) | 2004-03-16 |
| WO2001036425A3 (de) | 2002-01-10 |
| WO2001036425A2 (de) | 2001-05-25 |
| DK1228073T3 (da) | 2003-11-03 |
| BR0015487A (pt) | 2002-07-02 |
| HUP0203422A2 (hu) | 2003-02-28 |
| NO20022232L (no) | 2002-05-10 |
| AU1390701A (en) | 2001-05-30 |
| CA2391087A1 (en) | 2001-05-25 |
| CZ20021474A3 (cs) | 2002-07-17 |
| AU775886B2 (en) | 2004-08-19 |
| JP2003514821A (ja) | 2003-04-22 |
| SK6012002A3 (en) | 2002-09-10 |
| EP1228073B1 (de) | 2003-07-23 |
| DE50003036D1 (de) | 2003-08-28 |
| DE19954707A1 (de) | 2001-05-17 |
| ZA200204729B (en) | 2003-11-26 |
| NO20022232D0 (no) | 2002-05-10 |
| HUP0203422A3 (en) | 2004-12-28 |
| ATE245653T1 (de) | 2003-08-15 |
| PT1228073E (pt) | 2003-12-31 |
| KR20020049051A (ko) | 2002-06-24 |
| PL355098A1 (en) | 2004-04-05 |
| CN1390222A (zh) | 2003-01-08 |
| AR026421A1 (es) | 2003-02-12 |
| US6884800B1 (en) | 2005-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002113759A (ru) | Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII | |
| RU2002113750A (ru) | Производные пиррола в качестве ингибиторов фосфодиэстеразы VII | |
| ES2461967T3 (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
| JP3316661B2 (ja) | 〔(ヒドロキシフェニルアミノ)カルボニル〕ピロール | |
| EP1439837B1 (en) | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors | |
| AR016133A1 (es) | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria | |
| AU2018306619A1 (en) | Immunomodulator compounds | |
| IL110492A0 (en) | (di(ether or thioether) heteroaryl or fluoro substituted aryl) compounds, their preparation and pharmaceutical compositions containing them | |
| SK281240B6 (sk) | Deriváty kyseliny hydroxámovej, spôsob ich výroby, ich použitie na výrobu farmaceutických prostriedkov a farmaceutické prostriedky s ich obsahom | |
| RU2000132188A (ru) | Производные эпотилонов, их синтез и применение | |
| GB9930610D0 (en) | Tricyclic vascular damaging agents | |
| AR014903A1 (es) | Compuestos del tipo 4-amino-fenilalanina inhibidores de la adhesion de leucocitos intermediada por vla-4, compuesto que son droga de dichos compuestos,composiciones farmaceuticas, metodo para adherir vla-4 en una muestra biologica, metodo para tratar una condicion inflamatoria | |
| SK281318B6 (sk) | Amidy kyseliny hydroxyalkylidénkyanoctovej, farmaceutický prostriedok obsahujúci tieto zlúčeniny a ich použitie | |
| AU2002359291A1 (en) | Azole derivatives and pharmaceutical compositions containing them | |
| EP1438295A2 (en) | Azole derivatives and pharmaceutical compositions containing them | |
| WO1990008130A1 (en) | Polyunsaturated fatty acid derivatives, pharmaceutical compositions containing the same, method for the preparation thereof, and their use as medicament | |
| RU99127433A (ru) | Эрголиновые производные и их применение в качестве антагонистов рецепторов соматостатина | |
| JPH01246281A (ja) | 向精神性作用化合物及びその調製法 | |
| RU2002113746A (ru) | Производные изоксазола в качестве ингибиторов фосфодиэстеразы VII | |
| JP3122161B2 (ja) | γ−ラクトン免疫抑制剤 | |
| RU2002105518A (ru) | Гетероциклические соединения, ингибирующие ангиогенез | |
| RU2222541C2 (ru) | Оптически активные производные пирролопиридазина, способы их получения, фармацевтическая композиция и агент на их основе, способ лечения или профилактики язвенной болезни | |
| US6610850B2 (en) | Contrast media for angiography | |
| JPH024748A (ja) | 薬理作用を有するペプチド類 | |
| HUP0203790A2 (hu) | (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére |